INVESTORS
Raising $900K
OcuRegen™: a topical bioelectric therapy designed to accelerate corneal wound closure. 24-week plan to a nominated lead with an in vivo closure signal.
PRE-SEED DELIVERABLES
Week 16: ranked downselect
Week 24: rabbit closure signal & nominated lead
Provisionals filed & CRO reports
Investment snapshot
TARGET
PERSISTENT CORNEAL EPITHELIAL DEFECTS (PCED)
Non-healing corneal wounds (2+ weeks)
~100,000 cases/year
OUTPUT
DELIVERABLES
Week 16: ranked downselect of lead
Week 24: rabbit closure signal, nominated lead, & provisionals
GOAL
TARGET PRODUCT PROFILE (TPP)
≥50% faster closure vs. current standard of care (preclinical benchmarks)
EXPANSION
IMPAIRED HEALING CONDITIONS
Neurotrophic keratitis (NK) and broader healing surfaces, initially ocular-focused
ASK
RAISE
$900K SAFE; 24-week package
OPPORTUNITY
WHY NOW
Better options for bioelectric measurements and faster iteration translate to reduced risk
Timeline
Moat/IP & risk controls
IP STRATEGY
File provisional patents on the peptide fusion composition of matter (CoM) and its use in corneal healing; provisional filings on:
Composition
Methods: modulating corneal bioelectric PD to accelerate epithelial closure
Assays/gating thresholds as know-how
FREEDOM-TO-OPERATE (FTO)
Preliminary landscape scan complete; formal FTO search planned pre‑seed/early seed. We will review patents on similar peptides and device patents to ensure no overlap.
REGULATORY STRATEGY
Orphan Drug Designation precedent exists in PCED and we will apply to secure 7-year exclusivity. ODD + Fast Track are the near-term targets; breakthrough is pursued after clinical signal.
LOW POTENCY/ FAILURE IN VIVO
Early GO/NO-GO gates in ex vivo wound assays; expand lead library.
IMMUNOGENICITY
Sequence design to minimize T-cell epitopes; screen in silico & in vitro; confirm tolerability in preclinical tox.
REGULATORY/CMC DELAY
Engage ophthalmic-experienced CDMO; design formulation & analytical methods in parallel with efficacy.
IP CHALLENGES
File broad composition & method claims; build defensible know-how (formulation, assays, PD thresholds) as trade secrets.
OCULAR TOLERABILITY / CORNEAL TOXICITY
Corneal staining + IOP + histology + inflammation readouts.
OFF-TARGET ION TRANSPORT EFFECTS
Off-target ion transport effects (IOP, epithelial barrier).
Request materials
Deck and one pager are available for diligence. For discussion purposes only.